Lisata Therapeutics (Lisata Therapeutics) Cash, Cash Equivalents, Marketable Securities : $50.54 Mil (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Lisata Therapeutics Cash, Cash Equivalents, Marketable Securities?

Lisata Therapeutics's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($57.63 Mil) to Sep. 2023 ($54.39 Mil) but then stayed the same from Sep. 2023 ($54.39 Mil) to Dec. 2023 ($50.54 Mil).

Lisata Therapeutics's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($94.97 Mil) to Dec. 2022 ($69.23 Mil) and declined from Dec. 2022 ($69.23 Mil) to Dec. 2023 ($50.54 Mil).

Lisata Therapeutics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Lisata Therapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics Cash, Cash Equivalents, Marketable Securities Chart

Lisata Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

25.16

34.57

94.97

69.23

50.54

Lisata Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															69.23	61.10	57.63	54.39	50.54

Lisata Therapeutics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Lisata Therapeutics (NAS:LSTA) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Lisata Therapeutics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Lisata Therapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Lisata Therapeutics (Lisata Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (NAS:LSTA) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920

Website

https://www.lisata.com

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.

Executives

David W. Slack	director, officer: President & CBO	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Heidi Henson	director	2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Mohammad Azab	director	C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Erkki Ruoslahti	director	P.O. BOX 544, BUELLTON CA 93427
Steven S Myers	director	4695 MACAUTHUR COURT, EIGHTH FLOOR, NEWPORT BEACH CA 92660
Kristen K Buck	officer: EVP, R&D and CMO	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Todd C Girolamo	officer: CLO, SVP of Corp Dev	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Michael H. Davidson	director	OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Cynthia Schwalm	director	C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
David J Mazzo	director, officer: Chief Executive Officer	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Joseph Talamo	officer: SVP and CFO	CALADRIUS BIOSCIENCES, INC., 800 WESTCHESTER AVENUE. STE N341, RYE BROOK NY 10573
Douglas W Losordo	officer: See Remarks	13 FOX MEADOW RD, SCARSDALE NY 10583
Anford	10 percent owner	P.O. BOX 5039, SIOUX FALLS SD 57117
Health Sanford	10 percent owner	P.O. BOX 5039, SIOUX FALLS SD 57117